抗雄激素药物治疗皮肤病研究进展

doi:10.35541/cjd.20210024

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (9): 882-885.doi: 10.35541/cjd.20210024

抗雄激素药物治疗皮肤病研究进展

孙小洁刘毅

中国医学科学院北京协和医学院皮肤病医院临床药理及化妆品检测中心，南京 210042

收稿日期:2021-01-08 修回日期:2021-12-30 发布日期:2023-09-07
通讯作者: 刘毅 E-mail:liuyi@pumcderm.cams.cn

Anti-androgen drugs in the treatment of skin diseases

Sun Xiaojie, Liu Yi

Clinical Trial and Cosmetics Testing Center, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing 210042, China

Received:2021-01-08 Revised:2021-12-30 Published:2023-09-07
Contact: Liu Yi E-mail:liuyi@pumcderm.cams.cn

摘要/Abstract

摘要： 【摘要】雄激素是体内重要的性激素，参与多种皮肤病的发生发展，如痤疮、雄激素性脱发、多毛症等。抗雄激素药物可作用于雄激素合成途径及作用通路不同位点，拮抗雄激素作用，用于缓解并治疗相关疾病。近年来，该类药物治疗皮肤病取得一些研究进展，如克拉考特酮是近40年来首个用于痤疮局部治疗的新机制药物，度他雄胺用于治疗20岁以上男性雄激素性脱发，非那雄胺外用制剂用于雄激素性脱发和女性特发性多毛症疗效显著。本文综述近年抗雄激素药物治疗皮肤病取得的研究进展。

关键词: 雄激素拮抗药, 皮肤疾病, 治疗, 秃发, 多毛症, 痤疮

Abstract: 【Abstract】 Androgens are important sex hormones in the body, and are involved in the occurrence and development of various skin diseases, such as acne, androgenetic alopecia, hirsutism. Anti-androgen drugs can act on different sites in the androgen synthesis and functional pathways to antagonize the effects of androgens, and can be used in the alleviation and treatment of related diseases. In recent years, some research progress has been made in the treatment of skin diseases with anti-androgen drugs. For example, clascoterone is a first-in-class topical drug in the treatment of acne in the last 40 years, dutasteride can be applied in male patients aged over 20 years with androgenetic alopecia, and topical finasteride is markedly effective for the treatment of androgenetic alopecia, as well as idiopathic hirsutism in females. This review summarizes research progress in anti-androgen drugs in the treatment of skin diseases in recent years.

Key words: Androgen antagonists, Skin diseases, Therapy, Alopecia, Hirsutism, Acne

孙小洁刘毅. 抗雄激素药物治疗皮肤病研究进展[J]. 中华皮肤科杂志, 2023,56(9):882-885. doi:10.35541/cjd.20210024

Sun Xiaojie, Liu Yi. Anti-androgen drugs in the treatment of skin diseases[J]. Chinese Journal of Dermatology, 2023, 56(9): 882-885.doi:10.35541/cjd.20210024

参考文献 31

［1］	Olsen EA, Hordinsky M, Whiting D, et al. The importance of dual 5alpha⁃reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo⁃controlled study of dutasteride versus finasteride［J］. J Am Acad Dermatol, 2006,55（6）:1014⁃1023. doi: 10.1016/j.jaad.2006.05.007.
［2］	Cong TX, Hao D, Wen X, et al. From pathogenesis of acne vulgaris to anti⁃acne agents［J］. Arch Dermatol Res, 2019,311（5）:337⁃349. doi: 10.1007/s00403⁃019⁃01908⁃x.
［3］	Azarchi S, Bienenfeld A, Lo Sicco K, et al. Androgens in women: hormone⁃modulating therapies for skin disease［J］. J Am Acad Dermatol, 2019,80（6）:1509⁃1521. doi: 10.1016/j.jaad.2018.08. 061.
［4］	Hebert A, Thiboutot D, Stein Gold L, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials［J］. JAMA Dermatol, 2020,156（6）:621⁃630. doi: 10.1001/jamadermatol. 2020.0465.
［5］	Fields JR, Vonu PM, Monir RL, et al. Topical ketoconazole for the treatment of androgenetic alopecia: a systematic review［J］. Dermatol Ther, 2020,33（1）:e13202. doi: 10.1111/dth.13202.
［6］	Gupta AK, Lyons DC. The rise and fall of oral ketoconazole［J］. J Cutan Med Surg, 2015,19（4）:352⁃357. doi: 10.1177/1203475 415574970.
［7］	Santhosh P, George M. Clascoterone: a new topical anti⁃androgen for acne management［J］. Int J Dermatol，2021，60（12）:1561⁃165. doi: https://dx.doi.org/10.1111/ijd.15752.
［8］	张国毅, 林彤, 孙秋宁, 等. 口服屈螺酮炔雌醇片治疗女性中度寻常痤疮的多中心、随机、安慰剂对照临床研究［J］. 中华皮肤科杂志, 2015,48（2）:85⁃89. doi: 10.3760/cma.j.issn.0412⁃4030.2015.02.005.
［9］	Koo EB, Petersen TD, Kimball AB. Meta⁃analysis comparing efficacy of antibiotics versus oral contraceptives in acne vulgaris［J］. J Am Acad Dermatol, 2014,71（3）:450⁃459. doi: 10.1016/j.jaad.2014.03.051.
［10］	Thiboutot DM, Dréno B, Abanmi A, et al. Practical management of acne for clinicians: an international consensus from the Global Alliance to Improve Outcomes in Acne［J］. J Am Acad Dermatol, 2018,78（2 Suppl 1）:S1⁃S23. doi: 10.1016/j.jaad. 2017.09.078.
［11］	Garg V, Choi JK, James WD, et al. Long⁃term use of spironolactone for acne in women: a case series of 403 patients［J］. J Am Acad Dermatol, 2021,84（5）:1348⁃1355. doi: 10.1016/j.jaad.2020.12.071.
［12］	Suchonwanit P, Srisuwanwattana P, Chalermroj N, et al. A randomized, double⁃blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia［J］. J Eur Acad Dermatol Venereol, 2018,32（12）:2257⁃2263. doi: 10.1111/jdv.15171.
［13］	Suchonwanit P, Iamsumang W, Rojhirunsakool S. Efficacy of topical combination of 0.25% finasteride and 3% minoxidil versus 3% minoxidil solution in female pattern hair loss: a randomized, double⁃blind, controlled study［J］. Am J Clin Dermatol, 2019,20（1）:147⁃153. doi: 10.1007/s40257⁃018⁃0387⁃0.
［14］	赵辨. 保法止®（非那雄胺片）［J］. 临床皮肤科杂志, 2002,31（5）:307⁃307. doi: 10.3969/j.issn.1000⁃4963.2002.05.021.
［15］	Lee SW, Juhasz M, Mobasher P, et al. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women［J］. J Drugs Dermatol, 2018,17（4）:457⁃463.
［16］	Eun HC, Kwon OS, Yeon JH, et al. Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double⁃blind, placebo⁃controlled, phase III study［J］. J Am Acad Dermatol, 2010,63（2）:252⁃258. doi: 10.1016/j.jaad.2009.09.018.
［17］	Chung HC, Lee S, Lee WS. Long⁃term efficacy and safety of the dual 5⁃alpha reductase blocker dutasteride on male androgenetic alopecia patients［J］. J Dermatol, 2017,44（12）:1408⁃1409. doi: 10.1111/1346⁃8138.13710.
［18］	Vañó⁃Galván S, Saceda⁃Corralo D, Moreno⁃Arrones OM, et al. Effectiveness and safety of oral dutasteride for male androgenetic alopecia in real clinical practice: a descriptive monocentric study［J］. Dermatol Ther, 2020, 33（1）:e13182. doi: 10.1111/dth.13182.
［19］	Won YY, Lew BL, Sim WY. Clinical efficacy of oral administration of finasteride at a dose of 2.5 mg/day in women with female pattern hair loss［J］. Dermatol Ther, 2018,31（2）:e12588. doi: 10.1111/dth.12588.
［20］	Manabe M, Tsuboi R, Itami S, et al. Guidelines for the diagnosis and treatment of male⁃pattern and female⁃pattern hair loss, 2017 version［J］. J Dermatol, 2018,45（9）:1031⁃1043. doi: 10.1111/1346⁃8138.14470.
［21］	Kanti V, Messenger A, Dobos G, et al. Evidence⁃based （S3） guideline for the treatment of androgenetic alopecia in women and in men ⁃ short version［J］. J Eur Acad Dermatol Venereol, 2018,32（1）:11⁃22. doi: 10.1111/jdv.14624.
［22］	Paradisi R, Porcu E, Fabbri R, et al. Prospective cohort study on the effects and tolerability of flutamide in patients with female pattern hair loss［J］. Ann Pharmacother, 2011,45（4）:469⁃475. doi: 10.1345/aph.1P600.
［23］	Fernandez⁃Nieto D, Saceda⁃Corralo D, Jimenez⁃Cauhe J, et al. Bicalutamide: a potential new oral antiandrogenic drug for female pattern hair loss［J］. J Am Acad Dermatol, 2020,83（5）:e355⁃e356. doi: 10.1016/j.jaad.2020.04.054.
［24］	Ismail FF, Meah N, Trindade de Carvalho L, et al. Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients［J］. J Am Acad Dermatol, 2020,83（5）:1478⁃1479. doi: 10.1016/j.jaad.2020.03.034.
［25］	Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism［J］. Endocr Rev, 2000, 21（4）:347⁃362. doi: 10.1210/edrv.21.4.0401.
［26］	Tahvilian R, Ebrahimi A, Beiki O, et al. Preparation and clinical evaluation of Finastride gel in the treatment of idiopathic Hirsutism［J］. J Drug Assess, 2015,4（1）:12⁃18. doi: 10.3109/21556660.2015.1056525.
［27］	Tartagni MV, Alrasheed H, Damiani GR, et al. Intermittent low⁃dose finasteride administration is effective for treatment of hirsutism in adolescent girls: a pilot study［J］. J Pediatr Adolesc Gynecol, 2014,27（3）:161⁃165. doi: 10.1016/j.jpag.2013.09.010.
［28］	Moretti C, Guccione L, Di Giacinto P, et al. Combined oral contraception and bicalutamide in polycystic ovary syndrome and severe hirsutism: a double⁃blind randomized controlled trial［J］. J Clin Endocrinol Metab, 2018,103（3）:824⁃838. doi: 10.1210/jc.2017⁃01186.
［29］	Gray SL, Semla TP. Post⁃finasteride syndrome［J］. BMJ, 2019,366:l5047. doi: 10.1136/bmj.l5047.
［30］	Welk B, McArthur E, Ordon M, et al. Association of suicidality and depression with 5α⁃reductase inhibitors［J］. JAMA Intern Med, 2017,177（5）:683⁃691. doi: 10.1001/jamainternmed.2017. 0089.
［31］	Wei L, Lai EC, Kao⁃Yang YH, et al. Incidence of type 2 diabetes mellitus in men receiving steroid 5α⁃reductase inhibitors: population based cohort study［J］. BMJ, 2019,365:l1204. doi: 10.1136/bmj.l1204.

[1]	王雯竹王宝玺何艳艳徐浩翔. 化脓性汗腺炎/反常性痤疮的分型进展[J]. 中华皮肤科杂志, 2023, 56(9): 892-895.
[2]	王钰倩乔建军方红. 国内外斑秃诊疗指南/共识比较 [J]. 中华皮肤科杂志, 2023, 56(9): 885-888.
[3]	刘元香梁源赵欣荣孙玉娟马琳徐子刚. JAK抑制剂治疗儿童重症斑秃5例[J]. 中华皮肤科杂志, 2023, 56(9): 849-852.
[4]	荆可王媛李锁冯素英. 表现为环状红斑水疱的自身免疫性表皮下水疱病25例回顾性分析[J]. 中华皮肤科杂志, 2023, 56(9): 832-838.
[5]	陈耀龙刘辉姚志荣高兴华. 提升皮肤病领域指南和共识质量的策略与建议[J]. 中华皮肤科杂志, 2023, 56(9): 805-808.
[6]	袁心刚倪思利张建罗晓燕王华. 儿童黑素细胞痣的诊疗水平亟待提高[J]. 中华皮肤科杂志, 2023, 56(8): 782-786.
[7]	钟洁敏邵蕾梁毅敏黄琼霄夏曼琪刘玉梅. 射频火针与光动力疗法治疗面部中重度痤疮炎性皮损的疗效与安全性对比研究[J]. 中华皮肤科杂志, 2023, 56(8): 751-755.
[8]	宋志强陈奇权葛兰. 从特应性皮炎发病机制谈靶向治疗进展[J]. 中华皮肤科杂志, 2023, 56(8): 718-723.
[9]	王俊霞郭伟楠陈慧郝军峰李冰卫静宜赵涛. 自体脂肪移植治疗40例稳定期线状硬斑病疗效回顾分析[J]. 中华皮肤科杂志, 2023, 56(8): 762-765.
[10]	张晓东汪蔓雅朱英杰骆天德刘小明. 荧光染色法在面部皮肤蠕形螨检查中的应用评估[J]. 中华皮肤科杂志, 2023, 56(8): 766-769.
[11]	陈小敏张景展丁媛康晓静. 二甲双胍治疗银屑病的研究进展[J]. 中华皮肤科杂志, 2023, 56(8): 799-802.
[12]	周彤耿松梅. 生物制剂在大疱性类天疱疮治疗中的应用[J]. 中华皮肤科杂志, 2023, 56(8): 789-793.
[13]	李越吴金燕袁若月杨屈杨赵贤省朱宁文. 细胞治疗遗传性大疱性表皮松解症研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 698-702.
[14]	陶梦李敏刘乙萱刘韵祎姜沛彧张嘉文南宇晴许阳. 玫瑰痤疮与精神神经性疾病相关性研究进展[J]. 中华皮肤科杂志, 2023, 56(7): 693-697.
[15]	中华医学会皮肤性病学分会银屑病专业委员会. 中国银屑病诊疗指南（2023版）[J]. 中华皮肤科杂志, 2023, 56(7): 573-625.

抗雄激素药物治疗皮肤病研究进展

Anti-androgen drugs in the treatment of skin diseases

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 31

相关文章 15

Metrics

本文评价

推荐阅读 10